🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. strengths-based case management

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  2. tacrolimus

    Astellas Pharma Inc

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial

  3. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. telmisartan/amlodipine 40/5 mg fixed combination

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  5. tigecycline

    Wyeth is now a wholly owned subsidiary of Pfizer

    Community-Acquired Infections

    phase 3 small molecule completed

    1 trial

  6. tiotropium

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  7. tiotropium + olodaterol

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  8. tiotropium 5mcg/day

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  9. tiotropium high dose

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  10. tobacco abstinent contingent

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  11. trofosfamide, idarubicin, etoposide

    Solid Biosciences

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  12. valoctocogene roxaparvovec

    BioMarin Pharmaceutical Australia Pty Ltd

    Hemophilia A

    phase 3 mab active

    5 trials

  13. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  14. voclosporin

    Aurinia Pharmaceuticals

    Renal Transplantation

    phase 3 small molecule terminated

    1 trial

  15. volanesorsen

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 3 small molecule terminated

    1 trial

  16. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  17. vormatrogine

    Chongqing Precision Biotech Co., Ltd

    Epilepsy, Tonic-Clonic

    phase 3 small molecule active

    1 trial

  18. warfarin

    Bristol-Myers Squibb

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  19. warfarin

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  20. zilganersen

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 3 small molecule active

    1 trial

  21. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  22. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  23. zinc sulphate dietary supplement

    United Therapeutics Europe Ltd

    Nutrition

    phase 3 small molecule completed

    1 trial

  24. zodasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources